
Cardinal Health Beats Estimates at $67.5 Billion Revenue, $3.26 Adjusted EPS
Cardinal Health raised its fiscal 2027 non-GAAP EPS guidance to $12.80 to $13.00 from $12.40 to $12.60.
Cardinal Health Inc · NYSE · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Cardinal Health raised its fiscal 2027 non-GAAP EPS guidance to $12.80 to $13.00 from $12.40 to $12.60.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 19, 2026 | Mary C. Scherer Chief Accounting Officer | Sold | 2,302 | $237.39 $237.39-$237.40 | $546,473 |
| Aug. 19, 2026 | Jason M. Hollar Chief Executive Officer | Sold | 44,529 | $236.18 $233.22-$237.88 | $10.52 million |
| Aug. 18, 2026 | Jason M. Hollar Chief Executive Officer | Sold | 80,000 | $235.74 $234.56-$237.25 | $18.86 million |
| Aug. 18, 2026 | Stephen M. Mason CEO, GMPD Segment | Sold | 35,000 | $236.40 $234.59-$237.26 | $8.27 million |
| Aug. 18, 2026 | Deborah Weitzman CEO, PSS Segment | Sold | 7,354 | $235.45 $235.30-$237.44 | $1.73 million |
| Aug. 18, 2026 | Aaron E. Alt Chief Financial Officer | Sold | 42,000 | $236.34 $234.55-$237.26 | $9.93 million |
| Aug. 18, 2026 | Jessica L. Mayer Chief Legal/Compliance Officer | Sold | 29,436 | $236.19 $234.64-$237.31 | $6.95 million |
| Aug. 18, 2026 | Michelle D. Greene Chief Information Officer | Sold | 11,650 | $235.72 $234.57-$237.25 | $2.75 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCardinal Health Q1 FY27 non-GAAP EPS of $3.26 Beats $2.94 Consensus; Raises FY27 Guidance to $12.80-$13.00
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedCardinal Health signs binding letter of intent to extend CVS Health distribution agreements through June 2032 and reaffirms FY2027 EPS guidance of $12.40 to $12.60